Mutations creating hyperactive NOTCH1 are more common in the LCK inhibitor (dasatinib)-sensitive T-ALL patient samples, suggesting that these two signaling pathways might crosstalk [13]. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.